Silke Jamitzky
Muenster, NW 38149, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Ganglioside SSEA-4 in Ewing sarcoma marks a tumor cell population with aggressive features and is a potential cell-surface immune target.
Journal: Scientific reports
Published: October 07, 2023
Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers.
Journal: Cancers
Published: April 01, 2020
EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 15, 2019
Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers.
Journal: Frontiers in oncology
Published: September 04, 2018
Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Journal: Pediatric blood & cancer
Published: March 14, 2017
Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.
Journal: Oncoimmunology
Published: August 08, 2016
Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
Journal: Pediatric blood & cancer
Published: April 01, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026